Orphalan starts Phase 3 once-daily trientine trial against D-penicillamine in Wilson disease
Orphalan has launched the global Phase 3 TRADITiONAL study comparing an investigational once-daily trientine tetrahydrochloride formulation with D-penicillamine over 48 weeks.